Skip to main content

Nutrition is a topic that surrounds us every day. While we often talk about obesity and weight loss diets, we actually overlook that the opposite, meaning malnutrition or undernutrition, can be as detrimental. We speak of malnutrition when the body is not provided with enough nutrients, such as protein, carbohydrates, fats, vitamins, and minerals, which are essential for maintaining all vital body functions.

When our nutritional status is not optimal, the body becomes less resilient in facing challenges like illness, colds, or infections. Improving our nutritional status will therefore support and protect our body.

50 Years of Fresubin 

This year marks the 50th anniversary of Fresubin®, Fresenius Kabi’s trusted enteral nutrition brand. Since 1975, Fresubin® has supported over 300 million people in more than 75 countries, helping patients with their dietary management and therefore connection to life when everyday nourishment becomes a challenge. 

From chronic disease and critical illness to aging, cancer care, and rehabilitation, Fresubin® has played a vital role in restoring nutritional support. Because when eating becomes difficult or impossible, nutrition is no longer just fuel. It becomes a foundation of patients’ life. 

Fresenius announced today that its Operating Company Fresenius Kabi has introduced two new biosimilars in the U.S., Conexxence®(1) (denosumab-bnht) and Bomyntra®(2) (denosumab-bnht).

These denosumab biosimilars are approved by the FDA for all indications of the reference products, Prolia®(3) (denosumab) and Xgeva®(4) (denosumab), respectively. The biological medicines are used for the treatment of osteoporosis and other bone-related conditions.

This milestone represents Fresenius’ fifth and sixth biosimilars available in the U.S. It is a showcase of the company’s efforts to drive patient access to high-quality biological medicines. Earlier this year, Fresenius announced a global settlement with Amgen concerning its denosumab biosimilars. The company thereby continues the growth path of its BioPharma platform in line with #FutureFresenius.

Conexxence®(1)  and Bomyntra®(2)  are registered trademarks of Fresenius Kabi Deutschland GmbH in selected countries. Prolia®(3) and Xgeva®(4) are registered trademarks of Amgen Inc.

Read the full press release here.

Fresenius announced today that its Operating Company Fresenius Kabi has introduced two new biosimilars in the U.S., Conexxence®(1) (denosumab-bnht) and Bomyntra®(2) (denosumab-bnht).

These denosumab biosimilars are approved by the FDA for all indications of the reference products, Prolia®(3) (denosumab) and Xgeva®(4) (denosumab), respectively. The biological medicines are used for the treatment of osteoporosis and other bone-related conditions.

This milestone represents Fresenius’ fifth and sixth biosimilars available in the U.S. It is a showcase of the company’s efforts to drive patient access to high-quality biological medicines. Earlier this year, Fresenius announced a global settlement with Amgen concerning its denosumab biosimilars. The company thereby continues the growth path of its BioPharma platform in line with #FutureFresenius.

Conexxence®(1)  and Bomyntra®(2)  are registered trademarks of Fresenius Kabi Deutschland GmbH in selected countries. Prolia®(3) and Xgeva®(4) are registered trademarks of Amgen Inc.

Read the full press release here.

Shaping the future of healthcare

 

Discover why investing in Fresenius means investing in long-term healthcare innovation. Fresenius is a relevant, system-critical healthcare company. We combine innovative medicine, advanced medical technology, and the highest quality in clinical care to shape next-level therapies.

Watch the video for a quick summary of the key reasons to invest in Fresenius.
 

 

Q2/25 market sentiment

Listen to Felix Klein, Director of Investor Relations at Fresenius, as he shares his thoughts on the Q2/2025 results and feedback from the capital market.
 

6 reasons to invest

Across our therapy platforms, we deliver real impact for patients, professionals, and hospitals around the world. At the same time, we create long-term value for our shareholders.

Explore below a detailed overview of why Fresenius is both – a system-critical healthcare provider and a well-positioned company.
 

Global healthcare systems are facing critical challenges:

  • Longevity gap: Aging population and rising chronic diseases
  • Workforce gap: Rising shortage of medical specialists
  • Efficiency gap: Increasing healthcare spend 
     

Fresenius is part of the solution: We are actively addressing these global gaps by: 

  • driving affordable, innovative medicine and tailored nutrition
  • advancing integrated MedTech and digital ecosystems
  • strengthening our employer attractiveness
     

Our unique strength lies in the strong balance between two system-critical businesses: Fresenius Kabi and Fresenius Helios:

  • Fresenius Kabi supplies healthcare products for critically and chronically ill patients (Pharma, Biopharma, Nutrition & MedTech)
  • Fresenius Helios is Europe’s leading private hospital operator (Helios Germany & Quirónsalud Spain)

Both businesses hold leading market positions in attractive segments and are set for strong, sustainable organic growth and margin expansion.
 

In October 2022, Fresenius launched its #FutureFresenius strategy. Since then, we have made significant financial and structural progress, making our company more focused, adaptive, and performance driven. 

All key financial metrics in Full-Year 2024 compared to Full-Year 2022 improved – a clear sign that our strategy is working.

Visit our Fresenius Annual Report 2024 for more information.

 

Persistent macroeconomic volatility and emerging geopolitical tensions, Fresenius delivers consistent performance. This reflects the operating strength and continued execution of #FutureFresenius. While serving global markets, we foster a strong local presence. This way we are able to act quickly – also in uncertainties:

  • With our “Local for local” approach, we are closer to our customers. This means: in Europe for Europe, in Asia for Asia, in the U.S. for the U.S.

    90% of Group revenues are not exposed to U.S. tariffs, and 70% of total revenues are generated in Europe.
     
  • The “More in America” initiative specifically strengthens our strong local presence in U.S. manufacturing.

    In recent years, we have invested around 1 billion US dollars in production and logistics in the U.S. Around 70% of the medicines we sell in the U.S. are also manufactured there.

We kicked-off the next phase of #FutureFresenius – Rejuvenate – in 2025: Taking our performance to the next level! 

  1. This means upgrading our core businesses by doing what we are doing even better! Through patient care, customer service, better processes and operations, we’re creating value day by day!
     
  2. And scaling our three therapy platforms:
  • specialized (Bio)Pharma
  • targeted MedTech
  • holistic Care Provision 

Together they offer strong potential for future growth, innovation and digitalization and thus elevating performance.

Fresenius has transformed into a more focused, performance-driven organization with a strong culture of accountability. Our mission stand firm: to save and improve human lives with affordable, accessible, and innovative healthcare products and the highest quality in clinical care.

With over 100 years of experience, Fresenius has grown from a small business into a global healthcare company. Through #FutureFresenius, we’ve become simpler, more adaptive, and more competitive - delivering real impact to patients, caregivers, hospitals, employees, and shareholders alike. We are ready to lead and remain an employer of choice in today’s competitive healthcare landscape.

 

Discover more

Goals & Strategy

Read more

Analysts & Consensus

Read more

Financial Results

Read more

Sustainability

Read more

Contact

Nick Stone

Senior Vice President Investor Relations
Head of Investor Relations
T: +49 (0) 6172 608-97033
nick.stone@fresenius.com

Share Price

Data is delayed by 15 minutes.

Share price information
July 02

July 02, 2025
Geneva, Switzerland

Roadshow Geneva

July 01

July 01, 2025
Zurich, Switzerland

Roadshow Zurich

July 22

July 22, 2025
virtual

Barclays 2025 Conversations with the C-Suite in EU MedTech & Services – CEO Call

Test Video Snippet

A consulting room on a sunny morning in January at Madrid’s Villalba University Hospital, part of the Quirónsalud Hospital Group. The patient is visibly nervous. Her head is full of questions and diffuse fears – which is not uncommon. Dr. Natalia Ruiz Micó, Head of the Orthopedic Surgery and Traumatology Department, tries to reassure her. “Today we are going to talk about your upcoming hip operation …” That is how the doctor begins her consultation with the patient. This is also not uncommon. It is a conversation that will be held thousands of times a day here and at other hospitals. One thing, however, is different: Dr. Ruiz can fully concentrate on her patient. She doesn’t have to study the long medical records or take any notes, which means that she is less stressed than she used to be. That’s because these tasks are now handled by Scribe, an intelligent AI-based dictating machine for medical purposes that she opens on her work phone.

Scribe automatically transcribes and interprets doctor-patient conversations and converts them into a medical record.

Scribe was launched in the summer of last year. To date, more than 4,000 doctors in a total of 50 Quirónsalud hospitals across Spain have already used it to carry out over 500,000 consultations. Both doctors and patients report positive experiences of the technology. 

Among the first users was the Department of Orthopedic Surgery and Traumatology at Madrid’s Villalba University Hospital, where Dr. Ruiz is chief physician. While she talks to her patient, Scribe records the conversation, transcribes it, and summarizes the essential points and the resulting tasks. If necessary, the tool can even switch back and forth between several languages. 

The task of clinical documentation was previously a tedious job that was shared among the hospital teams. The secretary’s office took on some of it, as did the assistant doctors on the ward, but on many an occasion the team of treating doctors had to do it themselves. Scribe now saves everyone on the team a great deal of time – or to be more precise, the time previously spent on documentation and administrative work during each consultation. “Medical documentation is a very important aspect of our work, but it is also very time-consuming. It has been difficult to automate until now because it requires special knowledge,” says Dr. Ruiz.   

Quirónsalud developed the AI solution itself in conjunction with an IT partner and has been testing it since June 2024.

Technology with huge potential

Why is this now possible with Scribe? As is so often the case, the answer is AI, or more precisely, generative artificial intelligence, which has been enjoying a worldwide boom since the launch of ChatGPT. This type of AI can reliably process human speech and generate high-quality speech output in real time. Yet Scribe isn’t a product of Silicon Valley. Quirónsalud developed the AI solution itself in conjunction with an IT partner and has been testing it since June 2024.

“This technology has huge potential – and not just for Quirónsalud. Scribe helps to humanize healthcare and establish a much closer doctor–patient relationship. It frees medical teams from their administrative tasks and allows them to focus more on their patients,” says Dr. Jorge Short Apellániz, Deputy Medical Director of the Fundación Jiménez Díaz University Hospital in Madrid and one of the initiators of this project at Quirónsalud. 

Yet the tool doesn’t just save time. It also guides the doctor independently through the consultation. “Based on the information collected, Scribe also suggests necessary diagnostic tests or therapy options,” explains Dr. Emilio Calvo, Head of Orthopedic Surgery and Traumatology at the Fundación Jiménez Díaz University Hospital in Madrid. “So even during a consultation, the tool highlights possible courses of action,” says Calvo. He stresses, however, that the final decision is still made by the doctor.  

Based on the information collected, Scribe also suggests necessary diagnostic tests or therapy options.

Part of an intelligent clinic network

In order for Scribe to be able to make such intelligent suggestions, it has not only been specially trained, but is also embedded in an overarching digital system developed by Quirónsalud: the Casiopea hospital portal (see box for more information). All information is consolidated here, including the digital medical records – provided that the patients have consented to this. Casiopea has also supplied key training data for Scribe. “This high-quality and very specific data ensures that Scribe does not invent information, but instead delivers relevant results,” explains Dr. Short Apellániz. Furthermore, IT security and data protection are of the utmost importance where sensitive data of this nature is involved.

And how have patients reacted so far to the new development? Dr. Carolina Gotera, senior pulmonology physician at the Fundación Jiménez Díaz University Hospital, gets a lot of positive feedback when she explains the program: “Most patients congratulate us because they recognize the potential of AI and can see how innovative we are. They think it is good that we have more time for them, and their comments are therefore very positive.” 

Digital pioneer in Europe

With Scribe, Quirónsalud is continuing to consolidate its position as a digital pioneer in Europe – demonstrating how innovations in healthcare directly benefit people. “The tool improves communication between patients and medical staff, while minimizing any errors and misunderstandings,” summarizes Dr. Short. “At the same time, such tools increase efficiency and help to reduce the administrative burden for our employees. We can then all invest the time saved in interacting with the patients.” Quirónsalud plans to introduce the Scribe tool in all medical service areas and departments at its various hospitals across Spain in the course of 2025.  

"It's a game changer"

For the development of Scribe, the Quirónsalud Operations Team was honored with the Else Kröner Award 2025. This internal award recognizes Fresenius teams for outstanding, innovative, and exceptional initiatives that bring the Fresenius Principles to life and carry on Else Kröner’s legacy.

Discover the people and ideas behind the innovation - watch the full interview now.

Casiopea – at the heart of the digital hospital 

The Casiopea hospital portal – a so-called digital ecosystem – is a platform that Quirónsalud has been using throughout Spain since 2020. It optimizes patient flows and seamlessly connects all stages of the treatment process – from diagnosis and therapy to outpatient care. Almost eight million users in Spain are already connected to the system via a patient app. Doctors also use the Casiopea Mobility app on their smartphones, making it possible to arrange remote consultations, view laboratory results, and issue prescriptions, among many other things.

Fresenius is currently examining how the digital Casiopea platform can be transferred to Helios hospitals in Germany as part of a pilot project, taking into account the specific requirements of the German market. Among other things, it is working on a central communication interface between the doctor and patient.

Subscribe to